Home Applications 203975 Application 203975
Type NDA
Sponsor GLAXOSMITHKLINE Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 ANORO ELLIPTA UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE POWDER;INHALATION EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N203975-001 ANORO ELLIPTA UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER / INHALATION RLD, RS 2013-12-18
Orange Book patents# Current patent rows page 1 of 1 · 6 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N203975-001 8511304 2027-06-14 U-1476 Drug product 2014-01-09 N203975-001 8511304*PED 2027-12-14 Pediatric extension N203975-001 7488827 2027-12-18 Drug substance, Drug product 2014-01-09 N203975-001 11090294 2030-11-29 U-3203 2021-09-14 N203975-001 12396986 2030-11-29 Drug product 2025-09-19 N203975-001 9750726 2030-11-29 Drug product 2017-09-21
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 45 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N203975-001 ANORO ELLIPTA EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER / INHALATION RLD, RS 2013-12-18 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N203975-001 ANORO ELLIPTA EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER / INHALATION RLD, RS 2013-12-18 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N203975-001 ANORO ELLIPTA EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER / INHALATION RLD, RS 2013-12-18 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N203975-001 ANORO ELLIPTA EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER / INHALATION RLD, RS 2013-12-18 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N203975-001 ANORO ELLIPTA EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH POWDER / INHALATION RLD, RS 2013-12-18 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 17 · 646 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N203975-001 8511304 2027-06-14 U-1476 Drug product 2014-01-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N203975-001 8511304*PED 2027-12-14 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N203975-001 7488827 2027-12-18 Drug substance, Drug product 2014-01-09 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N203975-001 11090294 2030-11-29 U-3203 2021-09-14 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N203975-001 12396986 2030-11-29 Drug product 2025-09-19 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N203975-001 9750726 2030-11-29 Drug product 2017-09-21 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N203975-001 8511304 2027-06-14 U-1476 Drug product 2014-01-09 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203975-001 8511304*PED 2027-12-14 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N203975-001 7488827 2027-12-18 Drug substance, Drug product 2014-01-09 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203975-001 11090294 2030-11-29 U-3203 2021-09-14 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203975-001 12396986 2030-11-29 Drug product 2025-09-19 c2088c7a36db…2026-10-15 13:18:30 2026-09 N203975-001 9750726 2030-11-29 Drug product 2017-09-21 c2088c7a36db…2026-09-14 22:38:34 2026-08 N203975-001 8511304 2027-06-14 U-1476 Drug product 2014-01-09 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203975-001 8511304*PED 2027-12-14 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203975-001 7488827 2027-12-18 Drug substance, Drug product 2014-01-09 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203975-001 11090294 2030-11-29 U-3203 2021-09-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203975-001 12396986 2030-11-29 Drug product 2025-09-19 84e616aacf4f…2026-09-14 22:38:34 2026-08 N203975-001 9750726 2030-11-29 Drug product 2017-09-21 84e616aacf4f…2026-08-18 06:07:40 2026-07 N203975-001 8511304 2027-06-14 U-1476 Drug product 2014-01-09 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203975-001 8511304*PED 2027-12-14 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203975-001 7488827 2027-12-18 Drug substance, Drug product 2014-01-09 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203975-001 11090294 2030-11-29 U-3203 2021-09-14 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203975-001 12396986 2030-11-29 Drug product 2025-09-19 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N203975-001 9750726 2030-11-29 Drug product 2017-09-21 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N203975-001 8511304 2027-06-14 U-1476 Drug product 2014-01-09 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203975-001 8511304*PED 2027-12-14 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203975-001 7488827 2027-12-18 Drug substance, Drug product 2014-01-09 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203975-001 11090294 2030-11-29 U-3203 2021-09-14 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203975-001 12396986 2030-11-29 Drug product 2025-09-19 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N203975-001 9750726 2030-11-29 Drug product 2017-09-21 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203975-001 7498440 2025-04-27 Drug substance, Drug product 2014-01-09 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203975-001 8309572 2025-04-27 U-1476 2014-01-09 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203975-001 7439393 2025-05-21 U-1476 Drug substance, Drug product 2014-01-09 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203975-001 8183257 2025-07-27 U-1476 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203975-001 7439393*PED 2025-11-21 Pediatric extension 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203975-001 8511304 2027-06-14 U-1476 Drug product 2014-01-09 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203975-001 8511304*PED 2027-12-14 Pediatric extension 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203975-001 7488827 2027-12-18 Drug substance, Drug product 2014-01-09 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203975-001 11090294 2030-11-29 U-3203 2021-09-14 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N203975-001 12396986 2030-11-29 Drug product 2025-09-19 31067a03dcf5…
Observed Orange Book exclusivity history# openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 2 matching rows.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 10 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 0173-0869 Anoro Ellipta umeclidinium bromide and vilanterol trifenatate GlaxoSmithKline LLC NDA Current 0173-0869 Anoro Ellipta umeclidinium bromide and vilanterol trifenatate GlaxoSmithKline LLC NDA Current 0173-0869 Anoro Ellipta umeclidinium bromide and vilanterol trifenatate GlaxoSmithKline LLC NDA Current 0173-0869 Anoro Ellipta umeclidinium bromide and vilanterol trifenatate GlaxoSmithKline LLC NDA Current 0173-0869 Anoro Ellipta umeclidinium bromide and vilanterol trifenatate GlaxoSmithKline LLC NDA Current 0173-0869 Anoro Ellipta umeclidinium bromide and vilanterol trifenatate GlaxoSmithKline LLC NDA Current 0173-0869 Anoro Ellipta umeclidinium bromide and vilanterol trifenatate GlaxoSmithKline LLC NDA Current 0173-0869 Anoro Ellipta umeclidinium bromide and vilanterol trifenatate GlaxoSmithKline LLC NDA Current 0173-0869 Anoro Ellipta umeclidinium bromide and vilanterol trifenatate GlaxoSmithKline LLC NDA Current 0173-0869 Anoro Ellipta umeclidinium bromide and vilanterol trifenatate GlaxoSmithKline LLC NDA Current